HIVandHepatitis.com Coverage of Highlights from the 56th AASLD

HOME | Hepatitis B Main Section | Hepatitis C Main Section

HIVandHepatitis.com Coverage of Highlights from the
56^th Annual Meeting of the American
Association for the Study of Liver Diseases
November 11 - 15, 2005 San Francisco, California

HOME PAGE

Note: Unless otherwise stated, all references are to the Abstracts of the 56th Annual Meeting of the American Association for the Study of Liver Diseases, November 11 - 15, 2005, San Francisco, CA. Please note that this coverage is not associated officially or unofficially with the American Association for the Study of Liver Diseases.
Contributors: Ronald Baker, PhD and Marina Núñez , MD, PhD

Hepatitis C

New Experimental HCV Drugs in Development

HCV Protease Inhibitor SCH-503034 / Combo Treatment SCH-503034

HCV Protease Inhibitor VX-950

Valopicitabine (NM 283)

Consensus Interferon + Gamma Interferon +/- Ribavirin

Albuferon Plus Ribavirin

High-dose (double dose) Pegasys + Ribavirin

HIV-HCV Coinfection

FDA-approved HCV Treatments

PegIntron + Ribavirin

Pegasys + Ribavirin

African Americans

Pharmacokinetics

Genotypes

Adverse Events

Nonresponders

Viral Kinetics

Super Responders

Sustained Virologic Response (SVR)

Ribavirin - Flat dosing and Weight-based dosing

High dose peginterferon alfa-2b (PegIntron)

Hepatitis B

FDA-approved HBV Treatments
Adefovir dipivoxl (Hepsera) Epivir-HBV (Lamivudine) Pegasys (peginterferon alfa-2a)	Entecaivr (Baraclude) Intron A (interferon alfa-2a)